Arcturus Therapeutics Holdings Inc. (ARCT)
ARCT Stock Price Chart
Explore Arcturus Therapeutics Holdings Inc. interactive price chart. Choose custom timeframes to analyze ARCT price movements and trends.
ARCT Company Profile
Discover essential business fundamentals and corporate details for Arcturus Therapeutics Holdings Inc. (ARCT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 May 2013
Employees
174.00
Website
https://arcturusrx.comCEO
Joseph E. Payne
Description
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
ARCT Financial Timeline
Browse a chronological timeline of Arcturus Therapeutics Holdings Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$1.00, while revenue estimate is $3.11m.
Earnings released on 7 May 2026
EPS came in at -$0.95 surpassing the estimated -$1.03 by +7.39%, while revenue for the quarter reached $2.06m , missing expectations by -67.26%.
Earnings released on 3 Mar 2026
EPS came in at -$1.03 falling short of the estimated -$0.92 by -11.96%, while revenue for the quarter reached $7.20m , missing expectations by -54.75%.
Earnings released on 10 Nov 2025
EPS came in at -$0.49 surpassing the estimated -$0.80 by +38.71%, while revenue for the quarter reached $17.15m , beating expectations by +6.97%.
Earnings released on 11 Aug 2025
EPS came in at -$0.34 surpassing the estimated -$0.89 by +61.87%, while revenue for the quarter reached $28.30m , beating expectations by +50.28%.
Earnings released on 12 May 2025
EPS came in at -$0.52 surpassing the estimated -$1.58 by +67.09%, while revenue for the quarter reached $29.38m , beating expectations by +25.82%.
Earnings released on 6 Mar 2025
EPS came in at -$1.11 falling short of the estimated -$0.33 by -236.36%, while revenue for the quarter reached $22.77m , missing expectations by -43.01%.
Earnings released on 7 Nov 2024
EPS came in at -$0.26 surpassing the estimated -$0.70 by +62.86%, while revenue for the quarter reached $38.82m , missing expectations by -15.48%.
Earnings released on 5 Aug 2024
EPS came in at -$0.64 surpassing the estimated -$1.85 by +65.41%, while revenue for the quarter reached $45.98m , beating expectations by +34.24%.
Earnings released on 8 May 2024
EPS came in at -$1.00 surpassing the estimated -$1.17 by +14.53%, while revenue for the quarter reached $32.60m , beating expectations by +85.85%.
Earnings released on 7 Mar 2024
EPS came in at -$0.32 surpassing the estimated -$1.69 by +81.07%, while revenue for the quarter reached $28.21m , missing expectations by -25.48%.
Earnings released on 14 Nov 2023
EPS came in at -$0.61 surpassing the estimated -$1.79 by +65.92%, while revenue for the quarter reached $43.38m , beating expectations by +4.17%.
Earnings released on 7 Aug 2023
EPS came in at -$1.98 falling short of the estimated $0.09 by -2.30k%, while revenue for the quarter reached $9.57m , missing expectations by -80.28%.
Earnings released on 9 May 2023
EPS came in at $0.88 falling short of the estimated $2.92 by -69.86%, while revenue for the quarter reached $79.73m , beating expectations by +110.14%.
Earnings released on 28 Mar 2023
EPS came in at $4.43 surpassing the estimated $0.98 by +352.04%, while revenue for the quarter reached $160.05m , beating expectations by +120.21%.
Earnings released on 9 Nov 2022
EPS came in at -$1.33 surpassing the estimated -$2.01 by +33.83%, while revenue for the quarter reached $13.37m , beating expectations by +192.86%.
Earnings released on 9 Aug 2022
EPS came in at -$0.82 surpassing the estimated -$1.84 by +55.43%, while revenue for the quarter reached $27.09m , beating expectations by +763.69%.
Earnings released on 9 May 2022
EPS came in at -$1.94 falling short of the estimated -$1.29 by -50.39%, while revenue for the quarter reached $5.24m , missing expectations by -25.96%.
Earnings released on 28 Feb 2022
EPS came in at -$1.47 surpassing the estimated -$1.77 by +16.95%, while revenue for the quarter reached $5.79m , missing expectations by -60.72%.
Earnings released on 8 Nov 2021
EPS came in at -$2.05 falling short of the estimated -$1.40 by -46.43%, while revenue for the quarter reached $2.44m , missing expectations by -79.08%.
Earnings released on 9 Aug 2021
EPS came in at -$2.07 falling short of the estimated -$1.99 by -4.02%, while revenue for the quarter reached $2.00m , meeting expectations.
ARCT Stock Performance
Access detailed ARCT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
